Proactive investorsLogo Proactive Investors UK Website

Search field
Additional information
Additional Information
Market: NASDAQ
Sector: Pharmaceuticals
Epic: CSKI
News: Latest news
Web Site: China Sky Medical
Other Articles:

RSS - Subscribe to the News Today on Proactive UK ▼

Monday March 15, 11:21Diamondcorp: a big cash injection and a lot of work to do

70% of the new money was raised from current shareholders, reflecting a hefty amount of faith in the management to deliver.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Monday March 15, 08:34Robust Resources shares spike on record 82.5M gold-silver zone

The outstanding result came from hole LWD 062 which intersected gold and silver mineralisation over a drilled width of 82.5 metres. It is the widest intersection encountered by Robust in sixteen months of drilling to date.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Monday March 15, 09:01China's growth boosting commodity prices

The latest economic figures from China have put pressure on the dollar and boosted a number of high-yielding currencies, including the Australian dollar and the South African rand.

FULL ARTICLE ►
China Sky Medical

China Sky Medical

China Sky Medical engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products.

Tuesday, November 17, 2009

China Sky One Medical reports strong third quarter results

company news image

Pharma group China Sky One Medical Inc (Nasdaq: CSKI) reported strong third quarter results, mainly due to an enlarged sales team and a good contribution from acquisitions made in 2008.

Sales in the three months to end-September rose 45.5 percent from a year earlier to US$43.2 million, while net profit was up 25.3 percent at US12.5 million.

Sales of patch products totaled US$11.8 and accounted for 27.3 percent of revenue in the third quarter of 2009, versus US$13.0 million and 43.6 percent of revenue for the same period last year due to a change in the marketing strategy after the acquisition of Heilongjiang Tianlong Pharmaceutical Inc and Peng Lai Jin Chuang Pharmaceutical Co to focus on certain of their products.

Total revenues for nine months ended September 30 2009 increased 52.2 percent year-on-year to US$100.2 million and net profit reached US$29.2 million, up from of US$21.9 million previously.

As of September 30 2009, China Sky One Medical had US$56.3 million in cash and cash equivalents, approximately US$79.1 million in working capital, and no debt.

Chairman and CEO Yan-Qing Liu commented: "We are confident about the prospects for our business in 2009 and will continue to focus on increasing market share by both strengthening and further refining our sales and distribution network, building and enhancing our brand image, and seeking out strategic acquisitions that support our growth.”

"Based on our progress so far this year, we are reaffirming our guidance for the year. We expect 2009 full year revenue to increase by 40 percent, or approximately US$37 million, to US$130 million, driven by growth in all of our product sales categories. We expect 2009 net income will increase to approximately US$39 million,” he added.

AddThis Feed Button
Register here to be notified of future China Sky Medical articles.

Investors interested in China Sky Medical recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.